Early Neurodevelopmental Assessments Can ID Cerebral Palsy
By Elana Gotkine HealthDay Reporter
TUESDAY, May 7, 2024 -- Early neurodevelopmental assessments can predict cerebral palsy and its severity, according to a study published online May 6 in JAMA Network Open to coincide with the annual meeting of the Pediatric Academic Societies, held from May 2 to 6 in Toronto.
Abdul Razak, M.D., from Monash University in Melbourne, Australia, and colleagues conducted a diagnostic study to examine the effectiveness of early neurodevelopmental assessments at 3 to 4 months corrected age in identifying neurodevelopmental impairments. Participants were extremely preterm infants born at less than 28 weeks of gestation, extremely low birth-weight infants <1,000 g, and term encephalopathic infants; 116 infants were included.
The researchers found that the diagnosis of early cerebral palsy or high risk for cerebral palsy had a sensitivity and specificity of 92 and 84 percent, respectively, for predicting cerebral palsy, and 100 and 80 percent, respectively, for predicting moderate-to-severe cerebral palsy; accuracy of diagnosis was 85 and 81 percent, respectively, for predicting cerebral palsy and moderate-to-severe cerebral palsy. The absence of fidgety movements had an accuracy of 81 percent for predicting cerebral palsy, while Hammersmith Infant Neurological Examination (HINE) scores had good discrimination for prediction of cerebral palsy, with an area under the curve of 0.88. For cognitive impairment, predictive accuracy was 44 and 45 percent for a diagnosis of early cerebral palsy or high risk for cerebral palsy and the absence of fidgety movements, respectively. HINE scores also had poor discriminatory power for predicting cognitive impairment (area under the curve, 0.62).
"This emphasizes the crucial role of integrating these assessments into clinical practice, enabling early interventions with the potential to influence the progression of the disease," the authors write.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted May 2024
Read this next
AI-Assisted Contours Superior to Cognitively Defined Prostate Cancer Contours
WEDNESDAY, July 3, 2024 -- Artificial intelligence (AI)-assisted definition of prostate cancer contours reduces underestimation of the extent of prostate cancer, according to a...
Mean Cost of Bringing New Drug to U.S. Market Is $879.3 Million
TUESDAY, July 2, 2024 -- The mean cost of developing a new drug for the U.S. market is estimated to be $879.3 million when both drug development failure and capital costs are...
Patient–Primary Care Provider Language Concordance Tied to Better Outcomes
TUESDAY, July 2, 2024 -- Patient-family physician language concordance is associated with a lower risk for adverse outcomes, according to a study published online June 3...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.